Business Segment (Tables)

3 Months Ended

12 Months Ended

Mar. 31, 2023

Dec. 31, 2022

Business Segment [Abstract]

Schedule of operations by business segment

	Three Months Ended March 31,
	Revenue				Earnings
	2023		2022		2023			2022
FOXO Labs	$	7	$	32	$	(290	)	$	(504	)
FOXO Life		6		8		(647	)		(803	)
		13		40		(937	)		(1,307	)
Corporate and other (a)						(6,477	)		(10,738	)
Interest expense						(225	)		(322	)
Total	$	13	$	40	$	(7,639	)	$	(12,367	)

(a) Corporate and other includes stock-based compensation, including the consulting agreement, expense of $2,626 and depreciation and amortization expense of $929 for the three months ended March 31, 2023. For the three months ended March 31, 2022 corporate and other included stock-based compensation, depreciation, and changes in fair value of the convertible debentures of $231, $31, and $7,432 respectively. See Notes 4, 6, and 9 for additional information.

	Revenue				Earnings
	2022		2021		2022			2021
FOXO Labs	$	483	$	85	$	(2,769	)	$	(4,790	)
FOXO Life		28		35		(3,735	)		(2,381	)
		511		120		(6,504	)		(7,171	)
Corporate and other (a)						(87,311	)		(30,199	)
Interest expense						(1,440	)		(1,118	)
Total	$	511	$	120	$	(95,255	)	$	(38,488	)

(a) Corporate and other includes stock-based compensation, including the consulting agreement, Cantor Commitment Fee and vendor shares, expense of $17,708, depreciation and amortization expense of $1,487, change in fair value of convertible debentures and warrant liability expense of $26,104, $1,307 for impairment charge and $27,544 of other non-operating expenses for the year ended December 31, 2022. Additionally, the year ended December 31, 2022 included. For the year ended December 31, 2021 corporate and other included stock-based compensation, depreciation, changes in fair value of the convertible debentures and investment impairment of $131, $98, $21,703, and $400 respectively. See Notes 5, 6, 7, 9 and 11 for additional information.